biopharma dive | Biotech and Pharma Industry News

Keyword	CPC	PCC	Volume	Score	Length of keyword
biopharma dive	1.78	0.1	3185	67	14
biopharma	1.67	0.5	2451	47	9
dive	1.23	0.6	8333	35	4

Keyword	CPC	PCC	Volume	Score
biopharma dive	1.3	0.5	3925	78
biopharma dive ipo	0.35	0.9	8926	86
biopharma dive m&a tracker	1.52	0.6	1152	33
biopharma dive ned pagliarulo	1.25	0.1	1776	78
biopharma dive m&a	1.53	1	9281	74
biopharma dive logo	1.18	0.5	8984	27
biopharma dive opinion	1.5	0.3	3296	61
biopharma dive muckrack	0.3	0.2	3771	61
biopharma dive logo png	0.06	0.5	3447	98
biopharma dive media kit	0.65	0.7	1471	32
biopharma dive ben fidler	1.5	0.4	555	51
biopharma dive jacob bell	0.21	0.1	4310	57
biopharma dive deal tracker	0.14	0.6	9168	31
biopharma dive ipo tracker	1.91	1	8005	96
biopharma dive editorial calendar	0.2	0.2	9378	69
chris newman biopharma dive	0.89	0.8	3325	33

Search Results related to biopharma dive on Search Engine

Biotech and Pharma Industry News | BioPharma Dive
biopharmadive.com

https://www.biopharmadive.com/

WEBBioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.

DA: 4 PA: 63 MOZ Rank: 65

About Us | BioPharma Dive
biopharmadive.com

https://www.biopharmadive.com/about/

WEBAbout BioPharma Dive. BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships.

DA: 41 PA: 68 MOZ Rank: 14

Novartis raises forecasts as top drug sales beat Wall Street …
biopharmadive.com

https://www.biopharmadive.com/news/novartis-beat-raise-first-quarter-entresto-cosentyx/713968/

WEB2 days ago · The drugmaker also raised its sales guidance for the year and now expects growth of high single to low double digits. Shares rose by as much as 4.5% in Tuesday morning trading on the New York Stock Exchange. Novartis’ top-selling drugs Entresto and Cosentyx drove the beat, combining to bring in more than $3.2 billion in first quarter sales.

DA: 64 PA: 82 MOZ Rank: 26

Bristol Myers taps startup to boost cell therapy production | BioPharma
biopharmadive.com

https://www.biopharmadive.com/news/cellares-bristol-myers-car-t-manufacturing-cell-shuttle/713822/

WEB3 days ago · Dive Brief: Bristol Myers Squibb is turning to a manufacturing startup to help produce cancer cell therapies faster, announcing Monday a partnership with the South San Francisco, California-based Cellares. The deal, which reserves Cellares’ production capacity for Bristol Myers’ use, is worth up to $380 million in upfront and milestone ...

DA: 19 PA: 80 MOZ Rank: 92

Biotech | BioPharma Dive
biopharmadive.com

https://www.biopharmadive.com/topic/biotech/

WEBApr 18, 2024 · Biotech IPOs bounced back in first quarter, but backlog remains. Proceeds from biotech IPOs during the first three months of 2024 matched levels seen in the first quarters of 2019 and 2020, BioPharma Dive data show. By Gwendolyn Wu • April 12, 2024. Emerging biotech.

DA: 100 PA: 46 MOZ Rank: 12

Pharma | BioPharma Dive
biopharmadive.com

https://www.biopharmadive.com/topic/pharma/

WEBApr 15, 2024 · Top 5 stories from BioPharma Dive. A stock market run and a flurry of dealmaking have buoyed a sector that spent much of 2023 in a downturn. Can the momentum last? By BioPharma Dive staff

DA: 94 PA: 87 MOZ Rank: 12

Deep Dive | BioPharma Dive
biopharmadive.com

https://www.biopharmadive.com/deep-dive/

WEBDec 20, 2023 · Two decades and $200 billion: AbbVie’s Humira monopoly nears its end. The first biosimilar copy of Humira is set to arrive in the U.S. next week, testing both AbbVie and the market potential for knockoff biologic drugs. …

DA: 41 PA: 28 MOZ Rank: 80

Pfizer, Flagship join forces to hunt for 10 new drugs | BioPharma Dive
biopharmadive.com

https://www.biopharmadive.com/news/pfizer-flagship-research-alliance-10-drugs-biondi/688144/

WEBJul 18, 2023 · Dive Brief: Biotechnology startup creator Flagship Pioneering is teaming up with Pfizer to develop 10 new drug candidates, with each company pledging to invest $50 million in the new effort. Together, Flagship and Pfizer will take stock of the technologies available to the former firm and its affiliated startups, hunting for opportunities to ...

DA: 31 PA: 22 MOZ Rank: 42

Goldman Sachs gets into biotech investing with new venture fund
biopharmadive.com

https://www.biopharmadive.com/news/goldman-sachs-biotech-venture-fund-startups/703524/

WEBJan 3, 2024 · The companies are using a variety of technologies including precision medicine and AI to develop new treatments for cancer, neurological conditions and rare diseases. The venture capital activity stands in stark contrast to the slow pace of initial public offerings for biotechnology companies.

DA: 67 PA: 37 MOZ Rank: 59

Coronavirus vaccines are rolling out quickly. Here's ... - BioPharma Dive
biopharmadive.com

https://www.biopharmadive.com/news/coronavirus-vaccine-pipeline-types/579122/

WEBNov 24, 2021 · Coronavirus vaccines are rolling out quickly. Here’s where the pipeline stands. Last updated Nov. 24, 2021 • By Ned Pagliarulo, Jonathan Gardner, Shoshana Dubnow, Ben Fidler. Editor’s note: BioPharma Dive tracked COVID-19 vaccine development via this tracker from June 2020 through fall 2021.

DA: 85 PA: 87 MOZ Rank: 76